MX2021002215A - Derivados de tetrahidropiridopirimidina como moduladores de ahr. - Google Patents

Derivados de tetrahidropiridopirimidina como moduladores de ahr.

Info

Publication number
MX2021002215A
MX2021002215A MX2021002215A MX2021002215A MX2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A
Authority
MX
Mexico
Prior art keywords
tetrahydropyrido
pyrimidine derivatives
compounds
ahr modulators
ahr
Prior art date
Application number
MX2021002215A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Mete
Hitchin James R
Mark Graham
John King-Underwood
Philip Vellacott Thorne
Original Assignee
Jaguahr Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguahr Therapeutics Pte Ltd filed Critical Jaguahr Therapeutics Pte Ltd
Publication of MX2021002215A publication Critical patent/MX2021002215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021002215A 2018-08-24 2019-08-23 Derivados de tetrahidropiridopirimidina como moduladores de ahr. MX2021002215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (1)

Publication Number Publication Date
MX2021002215A true MX2021002215A (es) 2021-07-15

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002215A MX2021002215A (es) 2018-08-24 2019-08-23 Derivados de tetrahidropiridopirimidina como moduladores de ahr.

Country Status (14)

Country Link
US (1) US12221439B2 (cg-RX-API-DMAC7.html)
EP (1) EP3841102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021535213A (cg-RX-API-DMAC7.html)
KR (1) KR20210049135A (cg-RX-API-DMAC7.html)
CN (1) CN112739698A (cg-RX-API-DMAC7.html)
AU (1) AU2019323714A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110402A1 (cg-RX-API-DMAC7.html)
IL (1) IL281023A (cg-RX-API-DMAC7.html)
MX (1) MX2021002215A (cg-RX-API-DMAC7.html)
PH (1) PH12021550382A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101441SA (cg-RX-API-DMAC7.html)
WO (1) WO2020039093A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100931B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1663994B1 (en) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
SG11201810366WA (en) 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体

Also Published As

Publication number Publication date
US20210332041A1 (en) 2021-10-28
US12221439B2 (en) 2025-02-11
CA3110402A1 (en) 2020-02-27
BR112021003529A2 (pt) 2021-05-18
SG11202101441SA (en) 2021-03-30
KR20210049135A (ko) 2021-05-04
CN112739698A (zh) 2021-04-30
IL281023A (en) 2021-04-29
ZA202100931B (en) 2021-10-27
EP3841102B1 (en) 2022-09-14
WO2020039093A1 (en) 2020-02-27
AU2019323714A1 (en) 2021-03-25
JP2021535213A (ja) 2021-12-16
EP3841102A1 (en) 2021-06-30
PH12021550382A1 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
CO2022010241A2 (es) Inhibidores de sos1
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017002650A1 (es) Compuestos novedosos
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CL2019001495A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih.
CL2017001213A1 (es) Bencilpropargiléter como inhibidores de la nitrificación
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2022000481A2 (es) Inhibidores de enzimas
CO2018011819A2 (es) Inhibidores del potenciador del homólogo zeste 2
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
MX2018004977A (es) Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer